Eisai Primes Push For Biogen MS Range In India

Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.

Jigsaw
EISAI IS USING A MULTI-PRONGED APPROACH TO EXPAND THE MS MARKET IN INDIA

Eisai Pharmaceuticals India Pvt. Ltd. has started selling Biogen’s multiple sclerosis (MS) portfolio in India, a market where the condition remains vastly underdiagnosed and holds significant potential for expansion.

The India initiative is part of broader collaboration between Eisai Co. Ltd.. and Biogen Inc.. entered into last...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip